Loading...
15 items
2026-09-04
Tri Chemical Laboratories Inc. revised consolidated earnings guidance for the fiscal year ending January 31, 2027. For the year, the company expects net sales of JPY 29,500 million, operating profit of JPY 7,450 million, profit attributable to owners of parent of JPY 6,570 million, and basic earnings per share of JPY 202.17.
2026-09-04
Tri Chemical Laboratories Inc. revised consolidated earnings guidance for the fiscal year ending January 31, 2027. For the year, the company expects net sales of JPY 29,500 million compared to previous guidance of JPY 27,000 million, operating profit of JPY 7,450 million compared to previous guidance of JPY 6,000 million, profit attributable to owners of parent of JPY 6,570 million compared to previous guidance of JPY 4,600 million, and basic earnings per share of JPY 202.17 compared to previous guidance of JPY 141.55.
2026-06-08
Tri Chemical Laboratories Inc. reported earnings results for the first quarter ended April 30, 2026. For the first quarter, the company reported sales was JPY 7,488.67 million compared to JPY 6,569.92 million a year ago. Net income was JPY 1,855.38 million compared to JPY 1,207.6 million a year ago. Basic earnings per share from continuing operations was JPY 57.09 compared to JPY 37.16 a year ago.
2026-04-09
Tri Chemical Laboratories Inc. announced that they will report fiscal year 2026 results on Mar 13, 2026
2026-03-18
Tri Chemical Laboratories Inc. provided Consolidated Earnings Guidance for the Financial Year 2028 and 2029. For the year 2028, the company expects net sales of JPY 29,000 million, operating profit of JPY 7,050 million, profit attributable to owners of parent of JPY 4,600 million. For the year 2029, the company expects net sales of JPY 31,700 million, operating profit of JPY 8,650 million, profit attributable to owners of parent of JPY 6,120 million.
2026-03-17
Tri Chemical Laboratories Inc. provided consolidated earnings guidance for the six months ending July 31, 2026 and year ending January 31, 2027. For the six months, the company expects net sales of JPY 13,700 million, operating profit of JPY 2,960 million, profit attributable to owners of parent of JPY 2,190 million or JPY 67.39 basic earnings per share. For the year ending January 31, 2027, the company expects net sales of JPY 27,000 million, operating profit of JPY 6,000 million, profit attributable to owners of parent of JPY 4,600 million or JPY 141.55 basic earnings per share.
2026-03-17
Tri Chemical Laboratories Inc., at a Board of Directors meeting held on March 13, 2026, resolved to submit a proposal for “Partial Amendment to the Articles of Incorporation” to the 48th Annual General Meeting of Shareholders scheduled for April 27, 2026, as outlined below. The Company will reduce the term of office for Directors from two years to one year and amend Article 22 (Term of Office) of the current Articles of Incorporation to clarify the management responsibilities of Directors and establish a management structure capable of responding swiftly to changes in the business environment. The amendment is as follows: (The underline indicates the change.) Current Articles of Incorporation Amendment (Term of Office) Article 22 A Director’s term of office shall expire at the close of the annual general meeting of shareholders for, out of the fiscal years ending within two years after their election, the last fiscal year. (ii) The term of office of Directors who have been elected to fill a seat resulting from an increase in the authorized number of Directors or to fill a vacancy on the Board of Directors shall be until the end of the term of office of other incumbent Directors. (Term of Office) Article 22 A Director’s term of office shall expire at the close of the annual general meeting of shareholders for, out of the fiscal years ending within a year after their election, the last fiscal year. (ii) (Unchanged) Date of resolution at the Annual General Meeting of Shareholders April 27, 2026 (tentative) Effective date of the amendment to the Articles of Incorporation April 27, 2026 (tentative).
2026-03-17
Tri Chemical Laboratories Inc. proposed year end dividend of JPY 35.00 per share for the year ended January 31, 2026 compared to JPY 35.00 per share for the same period a year ago. Scheduled date of commencing dividend payments: April 28, 2026. Scheduled date of annual general meeting of shareholders: April 27, 2026. For the year 2027, the company expects to pay year end dividend of JPY 35.00 per share compared to JPY 35.00 per share a year ago.
2026-03-17
Tri Chemical Laboratories Inc., 2026 Earnings Call, Mar 13, 2026
2026-03-17
Tri Chemical Laboratories Inc. reported earnings results for the full year ended January 31, 2026. For the full year, the company reported sales was JPY 23,883.18 million compared to JPY 18,905.89 million a year ago. Net income was JPY 5,515.24 million compared to JPY 4,962 million a year ago. Basic earnings per share from continuing operations was JPY 169.72 compared to JPY 152.69 a year ago.
2026-03-13
Tri Chemical Laboratories Inc. announced that they will report first half, 2027 results on Aug 31, 2026
2026-03-13
Tri Chemical Laboratories Inc. announced that they will report Q1, 2027 results on May 29, 2026
2026-03-13
Tri Chemical Laboratories Inc., Annual General Meeting, Apr 27, 2026.
2026-03-13
Tri Chemical Laboratories Inc., Board Meeting, Mar 13, 2026. Agenda: To consider and approve Formulation of Medium-Term Management Plan; to consider submission of a proposal for "Partial Amendment to the Articles of Incorporation" to the 48th Annual General Meeting of Shareholders scheduled for April 27, 2026; and to consider resolution to nominate candidates for the positions of Directors and Auditor at the 48th Annual General Meeting of Shareholders scheduled for April 27, 2026.
2025-11-28
Tri Chemical Laboratories Inc. expected to report Fiscal Year 2026 results on March 13, 2026. This event was calculated by S&P Global (Created on November 28, 2025).
2026Q2 | 2026Q1 | 2025Q4 | 2025Q3 | 2025Q2 | 2025Q1 | 2024Q4 | 2024Q3 | 2024Q2 | 2024Q1 | 2023Q4 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenues | 26,213 | 24,802 | 23,883 | 23,811 | 23,306 | 22,201 | 18,906 | 16,136 | 13,598 | 11,292 | 11,246 |
Pretax Income Excl.Unusual Items | 7,815 | 7,936 | 7,089 | 7,691 | 7,701 | 7,154 | 6,583 | 5,188 | 4,050 | 3,050 | 3,277 |
Total Assets | 49,121 | 47,174 | 47,274 | 42,191 | 41,764 | 38,804 | 36,945 | 38,215 | 33,529 | 33,615 | 31,865 |
Total Liabilities | 10,873 | 10,413 | 11,126 | 7,672 | 8,475 | 7,487 | 5,357 | 8,417 | 4,757 | 6,118 | 4,295 |
Cash & Cash Equivalents | 10,078 | 7,798 | 7,279 | 5,421 | 7,096 | 7,991 | 9,439 | 10,953 | 9,530 | 11,154 | 10,497 |
Total Common Equity | 38,248 | 36,762 | 36,148 | 34,520 | 33,289 | 31,317 | 31,588 | 29,798 | 28,772 | 27,497 | 27,570 |
Book Value Per Share (BVPS) | 1,176.98 | 1,131.24 | 1,112.36 | 1,062.25 | 1,024.38 | 963.71 | 972.02 | 916.94 | 885.38 | 846.14 | 848.4 |
Net Change in Cash | 2,981 | -193 | -2,159 | -5,532 | -2,434 | -3,162 | -1,058 | -434 | -2,713 | -1,234 | -640 |
Capital Expenditure | -5,746 | -7,915 | -6,286 | -6,927 | -5,142 | -3,416 | -3,069 | -2,065 | -2,091 | -1,961 | -1,740 |
As of September 14, 2026, Tri Chemical Laboratories published financial results for the second quarter of 2026, with revenues of 7.22B yen and net income of 1.52B yen, representing a sharp 24.3% rise in revenues, along with a slight decrease of approximately 3.3% in EPS compared to the same quarter last year. A positive note is that for the 10th consecutive quarter, the company's revenue line has increased compared to last year's corresponding quarter, which demonstrates the company's stability and its ability to grow in the future.
Additionally, the EBITDA margin experienced a slight decrease from 32.96% in the corresponding quarter last year to 32.94%. Another figure worth noting is the free cash flow for the quarter, which was 2.55B yen, an increase of 3.23B yen from the previous year's corresponding period. Following the improvement in cash flow, the company's management returned an impressive amount of 46.99M yen which was paid as a dividend. It is important to note that the stock's dividend yield stands at approximately 1.2%, and it trades at 18.1x times current year's earnings, which is higher than the sector average (P/E 10.8x).
